ALT Q2 2019 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-32.7% YoY

Gross Profit

-$1M-81.1% margin

Operating Income

-$4M-218.4% margin

Net Income

-$3M-208.3% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-45.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$289,772

Balance Sheet

Total Assets

$62M

Total Liabilities

$6M

Stockholders' Equity

$56M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-32.7%
Gross Profit	-$1M	-$3M	+47.3%
Operating Income	-$4M	-$5M	+34.7%
Net Income	-$3M	-$9M	+62.9%